ANI Pharmaceuticals (ANIP) Stock Forecast, Price Target & Predictions
ANIP Stock Forecast
ANI Pharmaceuticals stock forecast is as follows: an average price target of $79.00 (represents a 42.88% upside from ANIP’s last price of $55.29) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ANIP Price Target
The average price target for ANI Pharmaceuticals (ANIP) is $79.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $94.00 to $60.00. This represents a potential 42.88% upside from ANIP's last price of $55.29.
ANIP Analyst Ratings
According to 4 Wall Street analysts, ANI Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ANIP stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ANI Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | Gary Nachman | Raymond James | $83.00 | $61.23 | 35.55% | 50.12% |
| Sep 11, 2024 | Les Sulewski | Truist Financial | $60.00 | $55.48 | 8.15% | 8.52% |
| Jun 26, 2024 | Oren Livnat | H.C. Wainwright | $94.00 | $65.49 | 43.53% | 70.01% |
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $87.00 | $68.06 | 27.83% | 57.35% |
| Aug 09, 2022 | - | Raymond James | $48.00 | $34.87 | 37.65% | -13.19% |
The latest ANI Pharmaceuticals stock forecast, released on Sep 18, 2024 by Gary Nachman from Raymond James, set a price target of $83.00, which represents a 35.55% increase from the stock price at the time of the forecast ($61.23), and a 50.12% increase from ANIP last price ($55.29).
ANI Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $71.50 | $81.00 |
| Last Closing Price | $55.29 | $55.29 | $55.29 |
| Upside/Downside | -100.00% | 29.32% | 46.50% |
In the current month, the average price target of ANI Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ANI Pharmaceuticals's last price of $55.29. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Truist Financial | Buy | Buy | Hold |
| Oct 11, 2024 | Raymond James | Buy | Buy | Hold |
| Oct 11, 2024 | Piper Sandler | - | Overweight | Initialise |
| Sep 18, 2024 | Raymond James | Outperform | Outperform | Hold |
| Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2022 | Raymond James | Outperform | Outperform | Hold |
ANI Pharmaceuticals's last stock rating was published by Truist Financial on Oct 22, 2024. The company gave ANIP a "Buy" rating, the same as its previous rate.
ANI Pharmaceuticals Financial Forecast
ANI Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $131.65M | $131.83M | $116.55M | $106.79M | $94.23M | $83.82M | $73.86M | $64.48M | $60.93M | $52.06M | $48.63M | $54.52M | $57.25M | $52.98M | $48.47M | $49.77M | $47.97M | $51.34M | $54.36M | $52.89M | $46.48M | $36.63M |
| Avg Forecast | $189.32M | $183.53M | $175.10M | $164.66M | $175.12M | $144.37M | $129.09M | $126.03M | $124.94M | $111.92M | $99.87M | $83.50M | $86.04M | $78.36M | $71.97M | $65.03M | $56.30M | $49.70M | $46.40M | $46.73M | $54.27M | $51.50M | $46.93M | $50.23M | $51.63M | $55.97M | $55.20M | $50.57M | $44.72M | $38.11M |
| High Forecast | $192.76M | $186.86M | $178.28M | $169.58M | $176.48M | $146.66M | $129.09M | $126.03M | $132.07M | $111.92M | $101.68M | $85.01M | $87.60M | $78.36M | $71.97M | $65.03M | $56.30M | $49.70M | $46.40M | $46.73M | $54.27M | $51.50M | $46.93M | $50.23M | $51.63M | $55.97M | $55.20M | $50.57M | $53.67M | $45.74M |
| Low Forecast | $186.12M | $180.43M | $172.14M | $160.70M | $173.48M | $142.08M | $129.09M | $126.03M | $121.16M | $111.92M | $98.18M | $82.08M | $84.59M | $78.36M | $71.97M | $65.03M | $56.30M | $49.70M | $46.40M | $46.73M | $54.27M | $51.50M | $46.93M | $50.23M | $51.63M | $55.97M | $55.20M | $50.57M | $35.78M | $30.49M |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.18% | 1.17% | 1.28% | 1.10% | 1.07% | 1.03% | 0.99% | 1.08% | 1.05% | 1.05% | 1.17% | 1.06% | 1.03% | 1.03% | 0.99% | 0.93% | 0.92% | 0.98% | 1.05% | 1.04% | 0.96% |
ANI Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $126.03M, with a low forecast of $126.03M, and a high forecast of $126.03M. ANIP's average Quarter revenue forecast represents a -4.27% decrease compared to the company's last Quarter revenue of $131.65M (Dec 23).
ANI Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $48.62M | $30.56M | $40.43M | $26.65M | $19.45M | $14.41M | $3.20M | $-3.97M | $-50.26M | $6.71M | $-4.30M | $13.43M | $11.07M | $13.93M | $-225.00K | $3.35M | $4.78M | $16.77M | $18.81M | $20.38M | $14.67M | $11.31M |
| Avg Forecast | $30.37M | $29.44M | $28.09M | $26.42M | $28.10M | $23.16M | $20.71M | $-12.40M | $20.04M | $17.96M | $16.02M | $-13.26M | $5.71M | $12.93M | $11.88M | $-14.18M | $9.29M | $8.20M | $7.66M | $7.91M | $8.95M | $8.50M | $7.74M | $2.79M | $8.52M | $9.24M | $9.11M | $15.52M | $14.09M | $11.75M |
| High Forecast | $30.92M | $29.98M | $28.60M | $27.21M | $28.31M | $23.53M | $20.71M | $-9.92M | $21.19M | $17.96M | $16.31M | $-10.61M | $6.85M | $12.93M | $11.88M | $-11.34M | $9.29M | $8.20M | $7.66M | $9.49M | $8.95M | $8.50M | $7.74M | $3.34M | $8.52M | $9.24M | $9.11M | $18.63M | $16.91M | $14.10M |
| Low Forecast | $29.86M | $28.95M | $27.62M | $25.78M | $27.83M | $22.80M | $20.71M | $-14.88M | $19.44M | $17.96M | $15.75M | $-15.91M | $4.56M | $12.93M | $11.88M | $-17.02M | $9.29M | $8.20M | $7.66M | $6.32M | $8.95M | $8.50M | $7.74M | $2.23M | $8.52M | $9.24M | $9.11M | $12.42M | $11.27M | $9.40M |
| Surprise % | - | - | - | - | - | - | - | - | 2.43% | 1.70% | 2.52% | -2.01% | 3.41% | 1.11% | 0.27% | 0.28% | -5.41% | 0.82% | -0.56% | 1.70% | 1.24% | 1.64% | -0.03% | 1.20% | 0.56% | 1.82% | 2.07% | 1.31% | 1.04% | 0.96% |
1 analysts predict ANIP's average Quarter EBITDA for Mar 24 to be $-12.40M, with a high of $-9.92M and a low of $-14.88M. This is -125.50% lower than ANI Pharmaceuticals's previous annual EBITDA (Dec 23) of $48.62M.
ANI Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $1.16M | $9.94M | $6.25M | $1.44M | $-4.24M | $-8.60M | $-14.92M | $-20.13M | $-51.05M | $-4.45M | $-14.11M | $86.00K | $-3.63M | $434.00K | $-12.34M | $-7.01M | $-4.83M | $3.90M | $6.58M | $449.00K | $2.25M | $1.15M |
| Avg Forecast | $29.88M | $27.42M | $25.55M | $21.54M | $28.21M | $21.07M | $18.43M | $-52.79M | $16.59M | $16.36M | $12.94M | $-56.46M | $-5.77M | $10.67M | $4.25M | $-60.39M | $14.30M | $13.52M | $11.69M | $50.63K | $18.23M | $17.07M | $14.43M | $-5.83M | $22.86M | $27.63M | $24.83M | $342.10K | $2.16M | $1.20M |
| High Forecast | $30.59M | $28.07M | $26.15M | $22.05M | $31.06M | $21.17M | $18.87M | $-42.24M | $17.42M | $16.37M | $13.24M | $-45.17M | $-4.62M | $10.67M | $4.25M | $-48.31M | $14.30M | $13.52M | $11.69M | $60.76K | $18.23M | $17.07M | $14.43M | $-4.66M | $22.86M | $27.63M | $24.83M | $410.51K | $2.59M | $1.44M |
| Low Forecast | $29.23M | $26.82M | $24.99M | $21.07M | $24.76M | $20.98M | $18.03M | $-63.35M | $15.35M | $16.36M | $12.65M | $-67.76M | $-6.92M | $10.67M | $4.25M | $-72.47M | $14.30M | $13.52M | $11.69M | $40.50K | $18.23M | $17.07M | $14.43M | $-7.00M | $22.86M | $27.63M | $24.83M | $273.68K | $1.73M | $957.51K |
| Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.61% | 0.48% | -0.03% | 0.74% | -0.81% | -3.51% | 0.33% | -3.57% | -0.33% | -1.21% | 1.70% | -0.20% | 0.03% | -0.86% | 1.20% | -0.21% | 0.14% | 0.27% | 1.31% | 1.04% | 0.96% |
ANI Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-52.79M, with a range of $-63.35M to $-42.24M. ANIP's average Quarter net income forecast represents a -4670.95% decrease compared to the company's last Quarter net income of $1.16M (Dec 23).
ANI Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $44.46M | $42.01M | $38.76M | $36.47M | $33.19M | $30.08M | $31.96M | $28.82M | $30.71M | $17.18M | $18.82M | $17.59M | $14.37M | $15.72M | $21.21M | $13.68M | $14.01M | $14.36M | $14.19M | $13.28M | $8.96M | $7.29M |
| Avg Forecast | $64.23M | $62.26M | $59.40M | $55.86M | $59.41M | $48.98M | $43.79M | $75.58M | $42.39M | $37.97M | $33.88M | $80.83M | $16.72M | $26.58M | $24.42M | $22.06M | $19.10M | $16.86M | $15.74M | $10.35M | $18.41M | $17.47M | $15.92M | $11.38M | $17.52M | $18.99M | $18.73M | $10.12M | $8.60M | $7.58M |
| High Forecast | $65.39M | $63.39M | $60.48M | $57.53M | $59.87M | $49.76M | $43.79M | $90.69M | $44.81M | $37.97M | $34.50M | $97.00M | $20.07M | $26.58M | $24.42M | $22.06M | $19.10M | $16.86M | $15.74M | $12.42M | $18.41M | $17.47M | $15.92M | $13.65M | $17.52M | $18.99M | $18.73M | $12.15M | $10.32M | $9.09M |
| Low Forecast | $63.14M | $61.21M | $58.40M | $54.52M | $58.85M | $48.20M | $43.79M | $60.46M | $41.10M | $37.97M | $33.31M | $64.67M | $13.38M | $26.58M | $24.42M | $22.06M | $19.10M | $16.86M | $15.74M | $8.28M | $18.41M | $17.47M | $15.92M | $9.10M | $17.52M | $18.99M | $18.73M | $8.10M | $6.88M | $6.06M |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.11% | 1.14% | 0.45% | 1.98% | 1.13% | 1.31% | 1.31% | 1.61% | 1.02% | 1.20% | 1.70% | 0.78% | 0.90% | 1.33% | 1.20% | 0.80% | 0.76% | 0.76% | 1.31% | 1.04% | 0.96% |
ANI Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $75.58M, based on 1 Wall Street analysts, with a range of $60.46M to $90.69M. The forecast indicates a 69.98% rise compared to ANIP last annual SG&A of $44.46M (Dec 23).
ANI Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| EPS | - | - | - | - | - | - | - | - | $0.06 | $0.46 | $0.35 | $0.06 | $-0.26 | $-0.53 | $-0.92 | $-1.25 | $-3.60 | $-0.37 | $-1.17 | $0.01 | $-0.30 | $0.04 | $-1.03 | $-0.59 | $-0.41 | $0.32 | $0.55 | $0.04 | $0.19 | $0.10 |
| Avg Forecast | $1.54 | $1.41 | $1.32 | $1.11 | $1.45 | $1.09 | $0.95 | $1.00 | $0.85 | $0.84 | $0.67 | $0.35 | $0.67 | $0.55 | $0.22 | $0.09 | $0.74 | $0.70 | $0.60 | $0.71 | $0.94 | $0.88 | $0.75 | $0.89 | $1.18 | $1.43 | $1.28 | $1.05 | $1.22 | $0.80 |
| High Forecast | $1.58 | $1.45 | $1.35 | $1.14 | $1.60 | $1.09 | $0.97 | $1.02 | $0.90 | $0.84 | $0.68 | $0.36 | $0.69 | $0.55 | $0.22 | $0.09 | $0.74 | $0.70 | $0.60 | $0.71 | $0.94 | $0.88 | $0.75 | $0.89 | $1.18 | $1.43 | $1.28 | $1.05 | $1.46 | $0.96 |
| Low Forecast | $1.51 | $1.38 | $1.29 | $1.09 | $1.28 | $1.08 | $0.93 | $0.97 | $0.79 | $0.84 | $0.65 | $0.34 | $0.66 | $0.55 | $0.22 | $0.09 | $0.74 | $0.70 | $0.60 | $0.71 | $0.94 | $0.88 | $0.75 | $0.89 | $1.18 | $1.43 | $1.28 | $1.05 | $0.98 | $0.64 |
| Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.55% | 0.52% | 0.17% | -0.39% | -0.96% | -4.18% | -13.39% | -4.86% | -0.53% | -1.93% | 0.01% | -0.32% | 0.05% | -1.38% | -0.66% | -0.35% | 0.22% | 0.43% | 0.04% | 0.16% | 0.13% |
According to 1 Wall Street analysts, ANI Pharmaceuticals's projected average Quarter EPS for Mar 24 is $1.00, with a low estimate of $0.97 and a high estimate of $1.02. This represents a 1557.24% increase compared to ANIP previous annual EPS of $0.06 (Dec 23).
ANI Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $0.61 | $10.00 | 1539.34% | - |
| IRWD | Ironwood Pharmaceuticals | $4.02 | $11.67 | 190.30% | Buy |
| PCRX | Pacira BioSciences | $16.64 | $35.00 | 110.34% | Hold |
| AMPH | Amphastar Pharmaceuticals | $44.16 | $66.00 | 49.46% | Buy |
| ANIP | ANI Pharmaceuticals | $55.25 | $79.00 | 42.99% | Buy |
| COLL | Collegium Pharmaceutical | $29.22 | $40.50 | 38.60% | Buy |
| ALKS | Alkermes | $27.55 | $36.38 | 32.05% | Hold |
| NBIX | Neurocrine Biosciences | $117.62 | $147.35 | 25.28% | Buy |
| PBH | Prestige Consumer Healthcare | $81.49 | $89.50 | 9.83% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $24.11 | $18.67 | -22.56% | Buy |